Roger Sidhu

4.0k total citations · 1 hit paper
29 papers, 904 citations indexed

About

Roger Sidhu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Roger Sidhu has authored 29 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Roger Sidhu's work include Colorectal Cancer Treatments and Studies (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (12 papers). Roger Sidhu is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (12 papers). Roger Sidhu collaborates with scholars based in United States, Belgium and Italy. Roger Sidhu's co-authors include Marc Peeters, Sergei Tjulandin, Timothy Price, Paul Ruff, Swaminathan Murugappan, Tae Won Kim, Kathy Zhang, Anne Thomas, Stefano Cascinu and Jin Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Roger Sidhu

29 papers receiving 888 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 339 citations Timothy Price, Marc Peeters et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Sidhu United States	13	715	388	248	165	156	29	904
Janja Ocvirk Slovenia	17	1.0k 1.4×	376 1.0×	179 0.7×	117 0.7×	231 1.5×	69	1.3k
Federico Nasroulah United States	11	824 1.2×	395 1.0×	153 0.6×	150 0.9×	159 1.0×	29	993
Vicente Alonso-Orduña Spain	7	832 1.2×	402 1.0×	140 0.6×	135 0.8×	148 0.9×	23	1.0k
Jian-Ming Xu China	12	578 0.8×	341 0.9×	152 0.6×	116 0.7×	98 0.6×	15	818
H. Kröning Germany	13	1.0k 1.5×	592 1.5×	199 0.8×	120 0.7×	254 1.6×	26	1.5k
Claus-Christoph Steffens Germany	7	972 1.4×	481 1.2×	164 0.7×	149 0.9×	132 0.8×	18	1.1k
R Castan France	4	829 1.2×	392 1.0×	166 0.7×	140 0.8×	117 0.8×	6	1.0k
Swantje Held Germany	17	920 1.3×	444 1.1×	318 1.3×	210 1.3×	230 1.5×	85	1.1k
José María Viéitez Spain	14	1.1k 1.5×	563 1.5×	195 0.8×	257 1.6×	132 0.8×	52	1.4k
C. Schlichting Germany	9	822 1.1×	405 1.0×	142 0.6×	128 0.8×	152 1.0×	16	1.2k

Countries citing papers authored by Roger Sidhu

Since Specialization

Citations

This map shows the geographic impact of Roger Sidhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Sidhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Sidhu more than expected).

Fields of papers citing papers by Roger Sidhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Sidhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Sidhu. The network helps show where Roger Sidhu may publish in the future.

Co-authorship network of co-authors of Roger Sidhu

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Sidhu. A scholar is included among the top collaborators of Roger Sidhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Sidhu. Roger Sidhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papadopoulos, Kyriakos P., Scott A. Laurie, Alexander I. Spira, et al.. (2023). 741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies. SHILAP Revista de lepidopterología. A835–A835. 4 indexed citations

Sidhu, Roger, et al.. (2020). Influence of the posterior cruciate ligament on kinematics of the knee during experimentally simulated clinical tests and activities of daily living. Journal of Biomechanics. 115. 110133–110133. 3 indexed citations

Hecht, J. Randolph, Jean‐Yves Douillard, Lee S. Schwartzberg, et al.. (2015). Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews. 41(8). 653–659. 45 indexed citations

Price, Timothy, Kathryn J. Newhall, Marc Peeters, et al.. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). e14623–e14623. 2 indexed citations

Cunningham, David, Niall C. Tebbutt, Ірина Давиденко, et al.. (2015). Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.. Journal of Clinical Oncology. 33(15_suppl). 4000–4000. 120 indexed citations

Peeters, Marc, Timothy Price, Tae Won Kim, et al.. (2015). Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology. 33(15_suppl). 3587–3587. 1 indexed citations

Price, Timothy, Marc Peeters, Tae Won Kim, et al.. (2014). Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology. 15(6). 569–579. 339 indexed citations breakdown →

Peeters, Marc, Salvatore Siena, Josep Tabernero, et al.. (2014). Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS).. Journal of Clinical Oncology. 32(15_suppl). 3557–3557. 3 indexed citations

Bendell, Johanna C., Chloé E. Atreya, Thierry André, et al.. (2014). Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).. Journal of Clinical Oncology. 32(15_suppl). 3515–3515. 45 indexed citations

10.

Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(3_suppl). LBA387–LBA387. 35 indexed citations

11.

Sidhu, Roger, Alan Rong, & Steve Dahlberg. (2013). Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials. Clinical Cancer Research. 19(5). 969–976. 36 indexed citations

12.

Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology. 24. iv23–iv24. 2 indexed citations

13.

Peeters, Marc, Kelly S. Oliner, Salvatore Siena, et al.. (2013). Comprehensive Kras and Nras Mutation Analysis: Predictive Biomarkers in a Phase 3 Panitumumab Monotherapy Study of Metastatic Colorectal Cancer (Mcrc). Annals of Oncology. 24. iv28–iv28. 2 indexed citations

14.

Douillard, Jean‐Yves, Salvatore Siena, Josep Tabernero, et al.. (2013). Overall Survival (OS) and Tumour Shrinkage Outcomes in Patients with Symptomatic/Asymptomatic Metastatic Colorectal Cancer (MCRC): Data From the Prime Study. Annals of Oncology. 24. iv32–iv32. 3 indexed citations

15.

Patterson, Scott D., Marc Peeters, Salvatore Siena, et al.. (2013). Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).. Journal of Clinical Oncology. 31(15_suppl). 3617–3617. 35 indexed citations

16.

Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 31(15_suppl). 3511–3511. 42 indexed citations

17.

Sobrero, Alberto F., Marc Peeters, Timothy Price, et al.. (2012). Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). 3535–3535. 4 indexed citations

18.

Douillard, Jean-Yves, Salvatore Siena, Josep Tabernero, et al.. (2012). Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(4_suppl). 531–531. 22 indexed citations

19.

LeBrun, David P., Tara Baetz, Patricia Farmer, et al.. (2008). Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs. Clinical Cancer Research. 14(2). 478–487. 6 indexed citations

20.

Pedra, Carlos Augusto Cardoso, Roger Sidhu, Brian W. McCrindle, et al.. (2004). Outcomes after balloon dilation of congenital aortic stenosis in children and adolescents. Cardiology in the Young. 14(3). 315–321. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact